Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review - Wikidata - wikimedia - TriplyDB

Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review

Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review

http://www.wikidata.org/entity/Q35019709

about

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide Pre-treatment considerations in childhood hypertension due to chronic kidney disease Vascular calcification: When should we interfere in chronic kidney disease patients and how?Stop chronic kidney disease progression: Time is approaching Lanthanum carbonate: safety data after 10 years Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012 Phosphate binders in chronic kidney disease: a systematic review of recent data.Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis.Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.Possibility of lanthanum absorption in the stomach.Phosphate binders in patients with chronic kidney disease.The effects of lanthanum chloride on proliferation and apoptosis of cervical cancer cells: involvement of let-7a and miR-34a microRNAs.Low parathyroid hormone levels after parathyroidectomy reduce cardiovascular mortality in chronic hemodialysis patients.Clinical Characteristics of Seven Patients with Lanthanum Phosphate Deposition in the Stomach.Lanthanum-Induced Mucosal Alterations in the Stomach (Lanthanum Gastropathy): a Comparative Study Using an Animal Model.Two Cases of Lanthanum Deposition in the Stomach in the Absence of Helicobacter pylori Infection.Inhibitory Effects of Lanthanum Chloride on Wear Particle-Induced Osteolysis in a Mouse Calvarial Model.Analysis of the parathyroid function in maintenance hemodialysis patients from Changchun, China.Treatment of hyperphosphatemia based on specific interactions between phosphorus and Zr(iv) active centers of nano-MOFs

P2860

Q26764806-398E5265-339C-4C9A-8411-E350EA8E37B0 Q26777613-B0CEB94A-3058-416B-A003-DE916C8F0029 Q28071582-F5D30F68-3853-4557-BD32-FEE15151FC3A Q28078020-C730BA55-E19D-488E-A66E-04593CF7268E Q28079982-7805FD6B-A82D-4177-97D8-FD45778F64BA Q30976543-8CC8EF2A-82B7-4E84-B874-F62DCB38C0D2 Q31039292-4E5BF3B0-4133-475E-B003-81F9337B6363 Q35207839-A85D4197-C214-49F0-95B5-3FA2B25471D7 Q35743692-6FED63E1-833F-4654-A629-CBCD2D3AA8B6 Q38202179-D5D29FFF-6BC7-4D9A-838A-FB732F2625E6 Q38268395-00A6C261-31A5-42EC-B008-66D33F2D33F1 Q38741675-024447CD-7453-4565-9E2B-302C38529B3C Q38824573-4192E5FE-4675-409E-9BC3-8301A8D6A5DC Q38959324-BD6E8F96-08CC-4B75-AA7F-F7D02E944A7B Q39155279-6009178F-4A47-44C0-975F-9D5C177CE1FD Q40698479-97F9BCB6-2358-455C-8096-B10FC3629A34 Q41042187-8F4470FE-AB25-46AE-8C62-294B8FCEC18E Q41183546-CB5B54C6-FFB8-4493-B395-D6726B39B662 Q48305601-02BB0CEC-25FF-495A-8BA7-1F239931225E Q49963357-15CF388D-56D8-4D45-AB24-24493896817E Q53199958-1A883239-C04D-40EC-BF1D-9571661EB6E3 Q55409247-EAE078D4-A1C2-4A73-830B-A916CC1FF8DC Q57470029-4D9200F8-5E28-425A-A6BE-E6691919A07C

P2860

Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review

http://www.wikidata.org/entity/Q35019709

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Efficacy and safety of lanthan ...... patients: a systematic review

@ast

Efficacy and safety of lanthan ...... patients: a systematic review

@en

type

label

Efficacy and safety of lanthan ...... patients: a systematic review

@ast

Efficacy and safety of lanthan ...... patients: a systematic review

@en

prefLabel

Efficacy and safety of lanthan ...... patients: a systematic review

@ast

Efficacy and safety of lanthan ...... patients: a systematic review

@en

P1433

Q35019709-3A2521ED-3378-491A-B2ED-14EA59596AEB

P1476

Q35019709-72AE3393-C6B8-421D-ACC7-29CAB9F2FAA9

P2093

Q35019709-11C40F36-3558-4864-8BFC-04A826DE82D0

Q35019709-27362408-C3C2-43E7-A712-C2E8512022F7

Q35019709-E7469459-6BD9-475E-98C1-16E2C4296C0C

Q35019709-F44592A4-965D-4431-B40A-9F5F0DDFF2D4

P2860

Q35019709-0187D0A6-863D-4185-B702-90A94E29F195

Q35019709-01BEDEAC-1277-47DC-BA6D-654FA7EA82BF

Q35019709-093A0619-0FAE-416D-869C-990F8E007184

Q35019709-09885611-E2AB-48A1-826A-8BF3F3020721

Q35019709-0ACF0110-A3DD-4821-9DCE-A43E371D4D7D

Q35019709-159578EA-624B-4A89-94F6-154D068397FD

Q35019709-176CEDBB-939F-450C-9353-CB80DA29172C

Q35019709-2268C794-E038-45BD-9DED-A85E35B4D822

Q35019709-22C187EE-34F6-4408-9A61-9DF1025E43D0

Q35019709-237E12C1-D3F3-4721-939E-86E8A30A58C2

P304

Q35019709-9CB097FC-D6AF-4522-9902-5F57CE04243E

P31

Q35019709-2875BDB5-FA25-4669-B81B-F1BC63075CA4

Q35019709-35dc62d3-5313-445f-a2eb-049ebb70ab75

P356

Q35019709-7B4A94A3-C243-4C46-A70D-BCB6CAA087C3

P478

Q35019709-8D48F804-8F06-47D7-A258-569146A4F125

P577

Q35019709-CED982CA-5C0C-4C05-972C-C4DC8EC261BC

P5875

Q35019709-BE41D245-16D6-46B8-8BCB-2E5A332C47AF

P698

Q35019709-DCA81C90-83FB-4182-84EC-5401E8659F73

P921

Q35019709-3002CDB0-3237-4883-A341-79385D667FF2

P932

Q35019709-4F8D8DDD-256F-479D-BEB7-4E2236E27618

P356

1471-2369-14-226

P1433

P1476

Efficacy and safety of lanthan ...... patients: a systematic review

@en

P2093

Chenglong Zhang

http://www.w3.org/2001/XMLSchema#string

Ji Wen

http://www.w3.org/2001/XMLSchema#string

Junming Fan

http://www.w3.org/2001/XMLSchema#string

Zi Li

http://www.w3.org/2001/XMLSchema#string

P2860

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

Lanthanum associated abnormal liver function tests in two patients on dialysis: a case report.

Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.

Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice.

Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.

How should hyperphosphatemia be managed in dialysis patients?

Medical management of secondary hyperparathyroidism in chronic renal failure.

Lanthanum carbonate (Shire).

Lanthanum carbonate: a new phosphate binder.

Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications.

P304

226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2369-14-226

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258053892

http://www.w3.org/2001/XMLSchema#string

P698

24134531

http://www.w3.org/2001/XMLSchema#string

P921

P932

3853136

http://www.w3.org/2001/XMLSchema#string